Цукровий Діабет: Роль Генетичних Факторів У Розвитку Захворюванн

Buryakovska, O. O.; Isayeva, Anna

doi:10.22141/2224-0721.13.1.2017.96763

Cited by 3 publications

(3 citation statements)

References 92 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Дипептидилпептидаза4 -многофункциональ ный фермент, расположенный на поверхности мно жества клеток, который способен инактивировать инкретины, включая ГПП1 и глюкозозависимый ин сулинотропный пептид, лишая их антигипергликеми ческих эффектов. Таким образом, при использовании иДПП4 восстанавливается пул активных ГПП1 и глю козозависимых инсулинотропных пептидов, увели чиваются глюкозозависимый синтез и секреция инсу лина, нормализуется гликемия [5].…”

Section: применение ингибиторов дипептидилпептидазы-4unclassified

Peculiarities of hypoglycaemic therapy in acute coronary syndrome in patients with type 2 diabetes mellitus

Bondareva¹,

Kovaleva²,

Lifshic³

2021

PKiK

View full text Add to dashboard Cite

This study assessed the features of the course of acute coronary syndrome in patients with diabetic neuropathy. Additionally, the role of antihyperglycaemic therapy as a cardio protection factor in this syndrome was determined by analysing the available literature data and clinical guidelines. Various antihyperglycaemic drug groups demonstrate possible molecular mechanisms of protection against ischemic cardiomyocytes. Cardiovascular disease treatment for patients with type 2 diabetes mellitus is rapidly developing. However, many aspects, including the exact mechanisms of the cardio protective action of antihyperglycaemic drugs, the presence of an additional positive effect of antihyperglycaemic drugs for patients with other diseases (e.g. kidney disease and chronic heart failure), and possible primary prevention of cardiovascular events in patients with type 2 diabetes, remain unclear.Received 11 September 2020. Revised 16 January 2021. Accepted 10 February 2021.Funding: The study did not have sponsorship.Conflict of interest: Authors declare no conflict of interest.

show abstract

Section: применение ингибиторов дипептидилпептидазы-4unclassified

Peculiarities of hypoglycaemic therapy in acute coronary syndrome in patients with type 2 diabetes mellitus

Bondareva¹,

Kovaleva²,

Lifshic³

2021

PKiK

View full text Add to dashboard Cite

show abstract

“…Хроническая гипергликемия при СД сопровождается повреждением, дисфункцией и недостаточностью различных органов, особенно глаз, почек, нервов, сердца и кровеносных сосудов [1]. СД 2-го типа является гетерогенным заболеванием, причём значимую роль играют генетические факторы [2].…”

Section: Genetics Proteomics and Metabolomics Abstractunclassified

“…Для оценки ассоциации изучаемого генетического полиморфизма с ожирением и СД 2-го типа из всех обследованных были сформированы группы для проведения анализа по типу «случай -контроль». Оценку ассоциации с ожирением изучали у 672 человек с ИМТ > 30 кг/м 2 (случай) и 378 человек с ИМТ < 30 кг/м 2 Носители варианта АА имели среднее снижение HbA1c на 0,53 %, у гетерозиготных пациентов отмечено снижение на 0,32, а носители минорного варианта СС имели увеличение на 0,2 % уровня HbA1c [37].…”

Section: ингибиторы дипептидилпептидазы-4unclassified

Pharmacogenetic Aspects of Type 2 Diabetes Treatment

Поздняков

Каграманян

Мирошников

et al. 2020

Acta biomedica scientifica

View full text Add to dashboard Cite

In this article, we analyze the role of different variants of the KCNJ11, TCF7L2, SLC22A1, SLC22A3, CYP2C9, CYP2C8, PPARγ genes polymorphisms in efficacy of diabetes mellitus pharmacotherapy. T allele of the KCNJ11 rs2285676 gene polymorphism and G allele of KCNJ11 rs5218 gene polymorphism are associated with the response to IDPP-4 therapy; the presence of KCNJ11 gene rs5210 polymorphism A allele is a predictor of poor response. The effect of rs7903146 polymorphism of TCF7L2 gene was evaluated on the response to treatment of patients taking linagliptin. Linagliptin significantly reduced HbA1c levels for all three rs7903146 genotypes (CC: –0.82 %; CT: –0.77 %; TT: –0.57 %). A significantly smaller effect of therapy was observed with the genotype with ТТ. The rs622342 polymorphism of SLC22A1 gene was studied in effectiveness of metformin. The researches demonstrated that carriers of variant AA had an average decrease of HbA1c of 0.53 %, heterozygous – decrease of 0.32 %, and carriers of a minor variant of SS had an increase of 0.2 % in the level of HbA1c. A significant effect of CYP2C9 polymorphisms on the pharmacokinetic parameters of PSM was noted. When studying the kinetics of glibenclamide, it was found that carriage of the allele *2 significantly reduces glibenclamide metabolism: homozygous carriers had clearance 90 % lower than homozygous carriers of the wild variant. The studies confirmed the association of the allelic variants of Thr394Thr and Gly482Ser of PPARγ gene with higher efficacy of the rosiglitazone. The data obtained from the analysis of the association of the Pro12Ala polymorphism of PPARγ gene and the response to therapy is contradictory. Thus the personalized approach, based on the knowledge of polymorphism options, will allow choosing the most effective drug with transparent kinetics for each individual patient.

show abstract